Abstract
There is a standard set of start-up, ongoing monitoring, and close-out requirements and procedures for all clinical trials. These generic requirements are discussed in other books and are not within the remit of this book. However, because of the nature of this therapeutic area, it is important to consider the particular extras and details that have to be evaluated, and this chapter provides an overview of these items. The sponsor must be aware of these items in a timely manner’all too often the novice will overlook an important detail until it becomes a crucial issue. This chapter will help ensure these kinds of errors are avoided.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
FDA Guidelines for the Preclinical and Clinical Evaluation of Agents used in the Prevention or Treatment of Postmenopausal Osteoporosis (1994). http://www.fda.gov/cder/guidance/osteo.pdf accessed 13/11/06
CPMP Notes for Guidance on Postmenopausal Osteoporosis in Women (2001). http://www.emea.eu.int/pdfs/human/ewp/055295en.pdf accessed 13/11/06
World Health Organization (1998). Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Geneva: World Health Organization.
Reginster, J. and Compston, J. (1997). GREES recommendations for the registration of new drugs in the prevention and treatment of osteoporosis. Calcif Tissue Int 60:488.
Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964, and revised by the 52nd World Medical Assembly, Edinburgh, 2000. http://www.wma.net/e/policy/b3.htm accessed 20/11/06
Miller, C.G. and Barden, H.S. (1994). Entrance criteria for clinical trials with DEXA. J Bone Miner Res 9(Suppl. 1):S209.
Looker, A.C., Wahner, H.W., Dunn, W.L. et al. (1998). Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–89.
Faulkner, K.G., Roberts, L.A. and McClung, M.R. (1996). Discrepancies in normative data between Lunar and Hologic DXA systems. Osteoporos Int 6:432–6.
Chen, Z., Maricic, M., Lund, P. et al. (1998). How the new Hologic hip normal reference values affect the densitometric diagnosis of osteoporosis. Osteoporos Int 8:423–7.
Hubbard, W.K. (1998). International Conference on Harmonization: Guidance on Statistical Principles for Clinical Trials. Federal Register 63:49583–98. http://www.fda.gov/cder/guidance/91698.pdf accessed 13/11/06
Blunt, B.A., Jones, D., Svensen, R.K. et al. (1998). Good clinical practice and audits for dual X-ray absorptiometry and X-ray imaging laboratories and quality assurance centers involved in clinical drug trials, private practice, and research. J Clin Densitom. 1:323–37.
Expert Working Group (Efficacy) (1996). International Conference on Harmonization: Structure and Content of Clinical Study Reports. Federal Register 61:37320–43. http://www.fda.gov/cder/guidance/iche3.pdf accessed 20/11/06
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag London Limited
About this chapter
Cite this chapter
Miller, C.G. (2007). Organization of the Clinical Trial by the Sponsor. In: Pearson, D., Miller, C.G. (eds) Clinical Trials in Osteoporosis. Clinical Trials. Springer, London. https://doi.org/10.1007/978-1-84628-587-5_5
Download citation
DOI: https://doi.org/10.1007/978-1-84628-587-5_5
Publisher Name: Springer, London
Print ISBN: 978-1-84628-389-5
Online ISBN: 978-1-84628-587-5
eBook Packages: MedicineMedicine (R0)